News
CHF: No letter yet, but threat of tariffs on pharmaceutical products – Commerzbank
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
Finally, don't discount legal challenges to the president's tariffs. An argument could be made that pharmaceutical products ...
A 200% tariff rate — even with a delay — will have a detrimental effect on drug prices and profit margins, analysts warn.
The drugmaker has invested $10 billion in Wake and Durham counties over the past 30 years. Biogen says that figure will ...
W hen Donald Trump’s tariffs are mentioned, you might recall his “Liberation Day” duties on uninhabited islands, his on-again ...
Already late with carrying out his administration's prior threats around pharmaceutical tariffs, President Donald Trump has ...
Drugmaker Swedish Orphan Biovitrum AB’s Chief Executive Officer Guido Oelkers said he doesn’t think tariff threats on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback